Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.31 |
| ▸ | NOS1 | P29475 | 1/20 | 0.31 |
| ▸ | NOS2 | P35228 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10326721 | 0.83 | MMP1 (0.33) | — | |
| SCHEMBL19173583 | 0.79 | NOS3 (0.30) | NOS3NOS1NOS2 | |
| SCHEMBL7892131 | 0.77 | — | — | |
| SCHEMBL7900716 | 0.70 | — | — | |
| SCHEMBL7537717 | 0.69 | — | — | |
| SCHEMBL7808288 | 0.68 | HSD11B1 (0.45) | HSD11B1 | |
| SCHEMBL18922374 | 0.68 | ZDHHC7 (0.31) | — | |
| SCHEMBL19173641 | 0.67 | — | — | |
| SCHEMBL4752634 | 0.67 | HSD11B1 (0.31) | HSD11B1 | |
| SCHEMBL12247796 | 0.66 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10172858-B2 | Combination pharmaceutical compositions and uses thereof | INTELLIKINE LLC (US) | 2019-01-08 | — | — | US | disclosed |
| US-20180117060-A1 | COMBINATION OF CATALYTIC MTORC 1/2 INHIBITORS AND SELECTIVE INHIBITORS OF AURORA A KINASE | MILLENNIUM PHARM INC (US) | 2018-05-03 | — | — | US | disclosed |
| US-20180117060-A1 | COMBINATION OF CATALYTIC MTORC 1/2 INHIBITORS AND SELECTIVE INHIBITORS OF AURORA A KINASE | MILLENNIUM PHARM INC (US) | 2018-05-03 | — | — | US | disclosed |
| US-9724354-B2 | Combination of catalytic mTORC1/2 inhibitors and selective inhibitors of Aurora A kinase | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| US-9724354-B2 | Combination of catalytic mTORC1/2 inhibitors and selective inhibitors of Aurora A kinase | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| US-20170209448-A1 | TREATMENT REGIMENS USING MULTIPLE PHARMACEUTICAL AGENTS | INTELLIKINE LLC | 2017-07-27 | — | — | US | disclosed |
| US-20170209448-A1 | TREATMENT REGIMENS USING MULTIPLE PHARMACEUTICAL AGENTS | INTELLIKINE LLC | 2017-07-27 | — | — | US | disclosed |
| US-9669032-B2 | Enhanced treatment regimens using mTOR inhibitors | INTELLIKINE LLC (US) | 2017-06-06 | — | — | US | disclosed |
| US-9669032-B2 | Enhanced treatment regimens using mTOR inhibitors | INTELLIKINE LLC (US) | 2017-06-06 | — | — | US | disclosed |
| US-20160287595-A1 | Combination Pharmaceutical Compositions and Uses Thereof | CALITHERA BIOSCIENCES, INC. | 2016-10-06 | — | — | US | disclosed |
| US-20140030256-A1 | BENZOXAZOLE KINASE INHIBITORS AND METHODS OF USE | INTELLIKINE LLC (US) | 2014-01-30 | — | — | US | disclosed |
| US-20130209543-A1 | ENHANCED TREATMENT REGIMENS USING MTOR INHIBITORS | INTELLIKINE LLC (US) | 2013-08-15 | — | — | US | disclosed |
| US-8476282-B2 | Benzoxazole kinase inhibitors and methods of use | INTELLIKINE LLC (US) | 2013-07-02 | — | — | US | disclosed |
| US-8476431-B2 | Benzoxazole kinase inhibitors and methods of use | Itellikine LLC (US) | 2013-07-02 | — | — | US | disclosed |
| US-8450480-B2 | — | — | 2013-05-28 | — | — | US | disclosed |
| US-8450329-B2 | — | — | 2013-05-28 | — | — | US | disclosed |
| US-20120294930-A1 | COMBINATION OF KINASE INHIBITORS AND USES THEREOF | INTELLIKINE LLC (US) | 2012-11-22 | — | — | US | disclosed |
| US-20120294930-A1 | COMBINATION OF KINASE INHIBITORS AND USES THEREOF | INTELLIKINE LLC (US) | 2012-11-22 | — | — | US | disclosed |
| US-20100190749-A1 | Benzoxazole kinase inhibitors and methods of use | FAETH THERAPEUTICS, INC. | 2010-07-29 | — | — | US | disclosed |
| US-20100184760-A1 | Benzoxazole kinase inhibitors and methods of use | FAETH THERAPEUTICS, INC. | 2010-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184760-A1 | Benzoxazole kinase inhibitors and methods of use | BMX, MTOR, PDPK1 | NOS3 2984/4885NOS1 4194/4885NOS2 3771/4885 |
| US-20160287595-A1 | Combination Pharmaceutical Compositions and Uses Thereof | CDC25C, CCNC, CDC25B | NOS3 3297/4885NOS1 3617/4885NOS2 3177/4885 |
| US-20130209543-A1 | ENHANCED TREATMENT REGIMENS USING MTOR INHIBITORS | RICTOR, MTOR, RPTOR | NOS3 3533/4885NOS1 3705/4885NOS2 3494/4885 |
| US-20140030256-A1 | BENZOXAZOLE KINASE INHIBITORS AND METHODS OF USE | BMX, MTOR, PDPK1 | NOS3 2984/4885NOS1 4194/4885NOS2 3771/4885 |
| US-20180117060-A1 | COMBINATION OF CATALYTIC MTORC 1/2 INHIBITORS AND SELECTIVE INHIBITORS OF AURORA A KINASE | AURKC, MTOR, AURKA | NOS3 4689/4885NOS1 4295/4885NOS2 4393/4885 |
| US-20100190749-A1 | Benzoxazole kinase inhibitors and methods of use | BMX, MTOR, PDPK1 | NOS3 2984/4885NOS1 4194/4885NOS2 3771/4885 |
| US-10172858-B2 | Combination pharmaceutical compositions and uses thereof | CDC25C, CCNC, CDC25B | NOS3 3297/4885NOS1 3617/4885NOS2 3177/4885 |
| US-20170209448-A1 | TREATMENT REGIMENS USING MULTIPLE PHARMACEUTICAL AGENTS | MPL, MTX2, SLC10A1 | NOS3 4051/4885NOS1 4292/4885NOS2 3791/4885 |
| US-20120294930-A1 | COMBINATION OF KINASE INHIBITORS AND USES THEREOF | MTOR, AKT2, MTMR1 | NOS3 2054/4885NOS1 2386/4885NOS2 2214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.